Testing a new PSMA imaging agent for prostate cancer
Part of Cancer clinical trials.
This trial tests a new radioactive imaging agent (61Cu-NODAGA-PSMA) to see if it can help find prostate cancer cells. It's for people with prostate cancer that shows up on a PSMA PET/CT scan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have prostate cancer confirmed by biopsy.
- You must be at least 18 years old.
- You must be in good general health (able to do daily activities).
- You must have a recent PSMA PET/CT scan (within 30 days) that shows PSMA-positive cancer.
- Your kidney function must be adequate (creatinine level 1.4 or lower, or a creatinine clearance of 60 mL/min or more).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to plan radiation for high-risk prostate cancer. Doctors will use a special PET scan (PSMA PET) to find the main tumor inside the prostate and give it a stronger dose of radiation, along with standard hormone therapy. This approach might improve outcomes for patients with aggressive disease.
This study compares a new PET/CT imaging agent (61Cu-NU101) with the standard one (Pylarify) to see if it's better at detecting prostate cancer that has spread to a few places. If you have oligometastatic prostate cancer, this trial might help improve how doctors find and monitor your cancer.
This trial tests a PSMA-targeted copper medicine used after a special PSMA PET/CT scan to find and treat prostate cancer that has spread. It’s for men whose testosterone is already very low and whose cancer is growing despite hormone-blocking medicines like enzalutamide or abiraterone.
This study tests a new imaging agent (68Ga-NYM032) used with PET/CT scans to help doctors better detect prostate cancer before surgery. If you have biopsy-confirmed prostate cancer and are planning to have your prostate removed, this trial may help evaluate whether this new imaging method improves cancer detection.
This trial studies a treatment that targets a protein called PSMA in people with prostate cancer. It may help shrink or control the cancer and is being tested in different risk groups and stages of disease.
This study looks at how well two different PSMA PET scans work for men with advanced prostate cancer. The scans help doctors see where the cancer is, which can guide treatment decisions and help you and your doctor plan next steps.
Hear when a new Prostate Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.